Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 7/23/2021 11:16:05 AM - Followers: 218 - Board type: Free - Posts Today: 1

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#12993   I took a look around the net this Zeppo 07/23/21 11:16:05 AM
#12991   Jess, we could use one of your wildly biotech_researcher 07/22/21 01:12:43 PM
#12990   Anybody else here into GTHX? Ganz 07/20/21 04:40:34 PM
#12989   Amen brother Ganz 07/20/21 10:05:19 AM
#12988   Reminder this evening that getting a drug across nferna 07/19/21 06:36:40 PM
#12987   Nothing wrong with taking profit. I have Cosa 07/19/21 04:31:16 PM
#12986   Savvy move Cosa, a lot of posters here Ganz 07/19/21 10:30:21 AM
#12985   “Yep, buying auph and BTC for insurance” LOL… biotech_researcher 07/17/21 11:46:49 AM
#12984   Yep, buying auph and BTC for insurance greggors 07/16/21 04:21:42 PM
#12983   Added a few more shares just now. Waiting Cosa 07/16/21 03:47:58 PM
#12982   BR loves Max, awwwwwww Ganz 07/16/21 11:44:43 AM
#12981   Cervelo, it seems like your one and only Jesspro 07/16/21 09:38:06 AM
#12980   It’s not Management to blame, they have some biotech_researcher 07/16/21 07:02:44 AM
#12979   amazing how many here are so negative on cervelo 07/15/21 06:00:49 PM
#12978   Maybe he was trying to use it as greggors 07/15/21 02:39:45 PM
#12977   in your attempt to spread vile here, zzaatt 07/15/21 02:04:26 PM
#12976   Right on Gregg Ganz 07/15/21 11:03:12 AM
#12975   Down again in pre market. Too expensive for biotech_researcher 07/15/21 07:05:13 AM
#12974   Zzaatt, in your attempt to spread vile here, biotech_researcher 07/15/21 06:27:27 AM
#12973   Or, in simpler English, "It's what they do." nsomniyak 07/14/21 09:13:25 PM
#12972   Time to load up again...don’t know how many greggors 07/14/21 08:17:13 PM
#12971   You (the gadfly) of all people should know zzaatt 07/14/21 06:24:38 PM
#12970   $14.40 to $11.50 in 30 days. Scrips are biotech_researcher 07/14/21 03:23:25 PM
#12969   I’m guessing it’s linked to Q2 results.AUPH always Ganz 07/14/21 02:29:27 PM
#12968   The problem with hedge funds is that they Zeppo 07/14/21 02:28:54 PM
#12967   You of all people should know being a" girlfriend 07/14/21 02:23:44 PM
#12966   $12.75 to $11.58 in 3 days. Guys, any biotech_researcher 07/14/21 02:18:26 PM
#12965   Jess, that article on hedge funds interest in biotech_researcher 07/14/21 12:41:08 PM
#12964   Just thought I would check in and see cervelo 07/14/21 12:06:44 PM
#12963   Good post Jess Ganz 07/14/21 10:03:48 AM
#12962   https://finance.yahoo.com/news/hedge-funds-coming-back-aurinia-165520993.html Jesspro 07/13/21 10:47:11 PM
#12961   Gibberish!!! zzaatt 07/13/21 05:22:24 PM
#12960   Dam, this is brutal. Breaking down bad. Fortunately, biotech_researcher 07/13/21 02:18:55 PM
#12959   That would be optimistic.. biotech_researcher 07/13/21 09:44:53 AM
#12958   I have checked with the author and he mdro 07/12/21 05:26:36 PM
#12957   It is a conservative number. It also shows Cosa 07/12/21 03:26:46 PM
#12956   I’m baaaaaack! biotech_researcher 07/12/21 10:11:03 AM
#12955   The 2Q21 $8.3m estimate from the recent seeking mdro 07/08/21 10:54:35 PM
#12954   If we could get 10% or 8,000 patientsIn zzaatt 07/08/21 08:31:29 PM
#12953   $4.9 million expected (article link below). To hit Cosa 07/08/21 06:06:36 PM
#12952   Ah don’t worry nferna, he’ll be back. That’s Jesspro 07/08/21 12:18:34 PM
#12951   Sorry to see you go BR.. nferna 07/08/21 09:44:49 AM
#12950   Done.. biotech_researcher 07/08/21 09:12:29 AM
#12949   ‘Thar she blows!! biotech_researcher 07/07/21 10:37:56 AM
#12948   Agree, Greggors. First line SOC for a BIC/FIC Jesspro 07/07/21 06:47:41 AM
#12947   Greggors, you mean $14 where it broke down? biotech_researcher 07/06/21 05:32:04 PM
#12946   It looks like They already know what the greggors 07/06/21 03:49:57 PM
#12945   They are all waiting to see what the biotech_researcher 07/06/21 02:19:40 PM
#12944   I don't do options a lot but these sonicty28 07/06/21 12:09:34 PM
#12943   I hear the Glickster is back to make biotech_researcher 07/02/21 05:18:10 PM
PostSubject
Consent Preferences